This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
September 2026 quarter: consolidated revenue up 20.8%, profit after tax up 30.4%
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts less than Nifty Midcap 150 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, revenue from operations rose 20.8% to Rs 118,357 lakh from Rs 97,994 lakh; profit after tax rose 30.4% to Rs 33,588 lakh from Rs 25,749 lakh a year earlier. For the half year, consolidated revenue was Rs 212,201 lakh and profit after tax was Rs 57,306 lakh. Auditors raised no concerns in the limited review. Other income included Rs 42.09 crore of tax-refund interest.
Strong quarterly growth supports positive sentiment, but Rs 42.09 crore of tax-refund interest helped profit and was not linked to core sales.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹1,184 Cr | ₹979.9 Cr | +20.8% |
| Operating profit | ₹386.6 Cr | ₹317.8 Cr | +21.6% |
| Profit after tax | ₹335.9 Cr | ₹257.5 Cr | +30.4% |
| EBITDA margin | 34.0% | 34.5% | −0.6 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.